SCHEMBL14645392

SCHEMBL14645392

Cn1ccc2ccc(C(=O)O)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.43
KDM4E B2RXH2 6/20 0.42
TDP1 Q9NUW8 2/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
ACMSD Q8TDX5 1/20 0.42
KMT2A Q03164 2/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40
MMP2 P08253 1/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
CYP2A6 P11509 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31721179 0.81 MAPK1 (0.41) KDM4EKMT2AMEN1MAPTRAB9A
SCHEMBL19231465 0.76 CDK4 (0.43) MGAMKDM4ETDP1ALOX15TSHR
SCHEMBL30547717 0.74 MGAM (0.47) MGAMKDM4ETDP1ALOX15TSHR
SCHEMBL31721224 0.74 ALOX15 (0.50) MGAMKDM4ETDP1ALOX15TSHR
SCHEMBL31721175 0.73 MGAM (0.42) MGAMKDM4ETDP1ALOX15TSHR
SCHEMBL22323347 0.72 DDB1 (0.39) KDM4EDDB1CRBNCYP2A6PARP1
SCHEMBL22204309 0.71 RXFP1 (0.40) KDM4ETDP1ALOX15TSHRACMSD
SCHEMBL27927347 0.71 MGAM (0.38) MGAMKDM4ETDP1ALOX15TSHR
SCHEMBL17417388 0.71 MGAM (0.38) MGAMKDM4ETDP1ALOX15TSHR
SCHEMBL15687389 0.70 NOTUM (0.48) MGAMKDM4ETDP1ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233111-B2 Pyrrolo pyrimidine derivatives NOVARTIS AG (CH) 2016-01-12 US claimed
EP-2729466-B1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2015-08-19 EP claimed
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2014-08-28 US claimed
EP-2729466-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2014-05-14 EP claimed
WO-2013008095-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2013-01-17 WO claimed
WO-2025231152-A1 COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION THE CLEVELAND CLINIC FOUNDATION (US) 2025-11-06 WO disclosed
US-9233111-B2 Pyrrolo pyrimidine derivatives NOVARTIS AG (CH) 2016-01-12 US disclosed
EP-2729466-B1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2015-08-19 EP disclosed
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2014-08-28 US disclosed
EP-2729466-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2014-05-14 EP disclosed
WO-2013008095-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES BTK, LCK, ZAP70 MGAM 4790/4885KDM4E 1348/4885TDP1 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.